CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 20, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	3,476	4,972	3,183	5,799	10,818	3,621
Market Cap Growth	15.37%	56.24%	-45.12%	-46.39%	198.74%	143.22%
Enterprise Value	1,767	3,474	1,452	3,527	9,501	3,033
Last Close Price	40.72	62.60	40.65	75.78	153.11	60.91
PE Ratio	-	-	-	15.36	-	54.16
PS Ratio	16.65	13.40	2656.64	6.34	15045.33	12.50
PB Ratio	1.79	2.64	1.70	2.42	6.50	3.85
P/TBV Ratio	2.14	2.64	1.70	2.42	6.50	3.86
P/FCF Ratio	-	-	-	12.68	-	72.43
P/OCF Ratio	-	-	-	10.76	-	63.89
EV/Sales Ratio	8.71	9.36	1211.76	3.86	13213.93	10.47
EV/EBITDA Ratio	-	-	-	9.01	-	58.93
EV/EBIT Ratio	-	-	-	9.44	-	64.89
EV/FCF Ratio	-	-	-	7.71	-	60.67
Debt / Equity Ratio	0.12	0.13	0.13	0.09	0.04	0.06
Debt / EBITDA Ratio	-	-	-	0.53	-	0.77
Debt / FCF Ratio	-	-	-	0.49	-	1.05
Asset Turnover	0.09	0.17	0.00	0.40	0.00	0.37
Quick Ratio	21.55	17.47	15.08	19.92	18.05	17.17
Current Ratio	21.64	17.54	15.30	20.17	18.21	17.29
Return on Equity (ROE)	-13.07%	-8.17%	-30.42%	18.59%	-26.80%	10.04%
Return on Assets (ROA)	-9.57%	-6.22%	-16.85%	10.19%	-15.31%	3.76%
Return on Capital (ROIC)	-10.04%	-6.56%	-17.74%	10.73%	-16.30%	4.22%
Earnings Yield	-6.89%	-3.09%	-20.43%	6.51%	-3.22%	1.85%
FCF Yield	-5.50%	-5.43%	-16.74%	7.88%	-2.37%	1.38%
Buyback Yield / Dilution	-5.11%	-1.90%	3.29%	-21.90%	-15.84%	-18.70%
Total Shareholder Return	-5.11%	-1.90%	3.29%	-21.90%	-15.84%	-18.70%

Source: S&P Capital IQ. Standard template. Financial Sources.